Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The prospective, single-arm, single-center, exploratory clinical study of Apatinib combined with Tegafur Gimeracil Oteracil Potassium Capsule in treating patients with Advanced esophageal squamous carcinoma

Trial Profile

The prospective, single-arm, single-center, exploratory clinical study of Apatinib combined with Tegafur Gimeracil Oteracil Potassium Capsule in treating patients with Advanced esophageal squamous carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
  • Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2019 Interim results (n=15) assessing clinical efficacy and safety of apatinib combined with Gimeracil/oteracil/tegafur in patients with advanced esophageal squamous cell carcinoma published in the Investigational New Drugs
    • 03 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top